BAFF Level Increased in Patients with Autoimmune Hemolytic Anemia

Overview

Journal Int J Clin Exp Med

Specialty General Medicine

Date 2015 Jun 12

PMID 26064287

Citations 2

Authors

Yu-Bing Zhao

Jun-Min Li

Bei-Wen Wei

Zi-Zhen Xu

Affiliations

Soon will be listed here.

Abstract

Introduction: BAFF (B-cell activating factor of the TNF family), an important regulator of B-cell, has been observed to be over-expressed in a variety of autoimmune diseases. Autoimmune hemolytic anemia (AIHA) is an acquired autoimmune disease occurred when antibodies directed against autologous red blood cells. We assessed serum levels of BAFF in AIHA patients with different serological characteristics.

Methods: Serum BAFF levels were measured in 44 AIHA patients with different direct antiglobulin test (DAT) results and 25 healthy controls. The correlation of BAFF expression with DAT results and serological characteristics was assessed.

Results: Serum levels of BAFF in AIHA patients were significantly higher than in healthy subjects (AIHA: 1382.7 ± 1412.8 pg/ml, healthy control: 725.0 ± 415.7 pg/ml, P = 0.0057). Serum BAFF levels were significantly higher in patients with IgG(+)C3(+) or IgG(+) than healthy controls (DAT: negative) (P = 0.012, 0.004, respectively). No significant correlations were presented between serum BAFF levels and four serological parameters: hemoglobine, percentage of reticulocyte, total serum bilirubin, and lactate dehydrogenase.

Conclusions: AIHA patients present higher serum BAFF levels than healthy controls, especially for those of IgG(+)C3(+) DAT result. This might lead to a new approach of AIHA treatment.

Citing Articles

Pathogenesis of Autoimmune Cytopenias in Inborn Errors of Immunity Revealing Novel Therapeutic Targets.

Cortesi M, Soresina A, Dotta L, Gorio C, Cattalini M, Lougaris V Front Immunol. 2022; 13:846660.

PMID: 35464467 PMC: 9019165. DOI: 10.3389/fimmu.2022.846660.

Thyroid eye disease: current and potential medical management.

Pouso-Diz J, Abalo-Lojo J, Gonzalez F Int Ophthalmol. 2020; 40(4):1035-1048.

PMID: 31919775 DOI: 10.1007/s10792-019-01258-7.

References

Chaudhary R, Das S . Autoimmune hemolytic anemia: From lab to bedside. Asian J Transfus Sci. 2014; 8(1):5-12. PMC: 3943148. DOI: 10.4103/0973-6247.126681. View

Lied G, Berstad A . Functional and clinical aspects of the B-cell-activating factor (BAFF): a narrative review. Scand J Immunol. 2010; 73(1):1-7. DOI: 10.1111/j.1365-3083.2010.02470.x. View

Kim S, Lee S, Choi I, Park Y, Choi C, Kim I . Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy. Eur J Haematol. 2008; 81(3):177-84. DOI: 10.1111/j.1600-0609.2008.01099.x. View

Gross J, Johnston J, Mudri S, Enselman R, Dillon S, Madden K . TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000; 404(6781):995-9. DOI: 10.1038/35010115. View

Wikman A, Axdorph U, Gryfelt G, Gustafsson L, Bjorkholm M, Lundahl J . Characterization of red cell autoantibodies in consecutive DAT-positive patients with relation to in vivo haemolysis. Ann Hematol. 2004; 84(3):150-8. DOI: 10.1007/s00277-004-0959-3. View

Thompson J, Bixler S, Qian F, Vora K, Scott M, Cachero T . BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001; 293(5537):2108-11. DOI: 10.1126/science.1061965. View

OREN H, Ucar C, Gulen H, Duman M, Irken G . Autoimmune hemolytic anemia occurring with myelodysplastic syndrome: report of a pediatric case and review of the literature. Ann Hematol. 2001; 80(9):540-2. DOI: 10.1007/s002770100332. View

Li Y, Jiang W, Rao H, Huang J, Xia Y, Huang H . Expression of BAFF and BAFF-R in follicular lymphoma: correlation with clinicopathologic characteristics and survival outcomes. PLoS One. 2012; 7(12):e50936. PMC: 3521766. DOI: 10.1371/journal.pone.0050936. View

Das S, Nityanand S, Chaudhary R . Clinical and serological characterization of autoimmune hemolytic anemia in a tertiary care hospital in North India. Ann Hematol. 2009; 88(8):727-32. DOI: 10.1007/s00277-008-0674-6. View

10.

Moore P, Belvedere O, Orr A, Pieri K, LaFleur D, Feng P . BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999; 285(5425):260-3. DOI: 10.1126/science.285.5425.260. View

11.

Andreoli L, Reggia R, Pea L, Frassi M, Zanola A, Cartella S . Belimumab for the treatment of refractory systemic lupus erythematosus: real-life experience in the first year of use in 18 Italian patients. Isr Med Assoc J. 2014; 16(10):651-3. View

12.

Mackay F, Woodcock S, Lawton P, Ambrose C, Baetscher M, Schneider P . Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999; 190(11):1697-710. PMC: 2195729. DOI: 10.1084/jem.190.11.1697. View

13.

Semple J, Freedman J . Autoimmune pathogenesis and autoimmune hemolytic anemia. Semin Hematol. 2005; 42(3):122-30. DOI: 10.1053/j.seminhematol.2005.04.002. View

14.

Sekiguchi Y, Shimada A, Imai H, Wakabayashi M, Sugimoto K, Nakamura N . A case of recurrent autoimmune hemolytic anemia during remission associated with acute pure red cell aplasia and hemophagocytic syndrome due to human parvovirus B19 infection successfully treated by steroid pulse therapy with a review of the.... Int J Clin Exp Pathol. 2014; 7(5):2624-35. PMC: 4069955. View

15.

Vallerskog T, Heimburger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C . Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2006; 8(6):R167. PMC: 1794511. DOI: 10.1186/ar2076. View

16.

Tian Y, Wang C, Liu J, Wang H . Primary Biliary Cirrhosis-Related Autoimmune Hemolytic Anemia: Three Case Reports and Review of the Literature. Case Rep Gastroenterol. 2010; 3(2):240-247. PMC: 2988964. DOI: 10.1159/000229189. View

17.

Cheema G, Roschke V, Hilbert D, Stohl W . Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001; 44(6):1313-9. DOI: 10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S. View

18.

Jordan N, DCruz D . Belimumab for the treatment of systemic lupus erythematosus. Expert Rev Clin Immunol. 2014; 11(2):195-204. DOI: 10.1586/1744666X.2015.996550. View

19.

Gehrs B, Friedberg R . Autoimmune hemolytic anemia. Am J Hematol. 2002; 69(4):258-71. DOI: 10.1002/ajh.10062. View